Announcements Trials
Browse Landscape

Status

Unknown 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 9Observational 2Expanded_access 1

Sponsor

Cancer Type

NET 2Endocrine 2

Conditions

Neuroendocrine Tumors 1Neuroendocrine Tumor Grade 3 1

Interventions

lutetium Lu 177 dotatate 6Magnetic Resonance Spectroscopy 3Data Collection 3telotristat ethyl 2surufatinib 2Somatostatin 2Positron-Emission Tomography 2Everolimus 2Drug Therapy 2Biopsy 2lanreotide 1copper dotatate CU-64 1Surveys and Questionnaires 1Surgical Procedures, Operative 1Sunitinib 1Sorafenib 1Salvage Therapy 1Radionuclide Imaging 1Radiomics 1Radiofrequency Ablation 1Quality of Life 1Plastic Surgery Procedures 1Phlebotomy 1Patient Reported Outcome Measures 1Octreotide 1Molecular Diagnostic Techniques 1Lutetium-177 1Lutetium 1Liver Transplantation 1Laparoscopy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Observational × surufatinib × NET × Clear all
NCT07534371 2026-04-16

Analysis of Optimal Treatment Sequencing of Surufatinib and Somatostatin Analogs in Neuroendocrine Tumors: A Retrospective Cohort Study

West China Hospital

Active not recruiting
500 enrolled
EndocrineNET

Neuroendocrine Tumors

NCT05973968 2023-08-04

Surufatinib in G3 Neuroendocrine Tumors

Qilu Hospital of Shandong University

Unknown
32 enrolled
EndocrineNET

Neuroendocrine Tumor Grade 3

Data powered by HemOnc (CC BY 4.0) Colophon âš¡